Citation Formats
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

L. M. Ruilope Et Al. , "Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial," AMERICAN JOURNAL OF NEPHROLOGY , vol.50, no.5, pp.345-356, 2019

Ruilope, L. M. Et Al. 2019. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. AMERICAN JOURNAL OF NEPHROLOGY , vol.50, no.5 , 345-356.

Ruilope, L. M., Agarwal, R., Anker, S. D., Bakris, G. L., Filippatos, G., Nowack, C., ... Kolkhof, P.(2019). Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. AMERICAN JOURNAL OF NEPHROLOGY , vol.50, no.5, 345-356.

Ruilope, Luis Et Al. "Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial," AMERICAN JOURNAL OF NEPHROLOGY , vol.50, no.5, 345-356, 2019

Ruilope, Luis M. Et Al. "Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial." AMERICAN JOURNAL OF NEPHROLOGY , vol.50, no.5, pp.345-356, 2019

Ruilope, L. M. Et Al. (2019) . "Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial." AMERICAN JOURNAL OF NEPHROLOGY , vol.50, no.5, pp.345-356.

@article{article, author={Luis M. Ruilope Et Al. }, title={Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial}, journal={AMERICAN JOURNAL OF NEPHROLOGY}, year=2019, pages={345-356} }